IP Library Granted Patent US 7,144,723
Granted Patent B2
US 7,144,723 · App. 09/991,518 · Granted Dec 5, 2006

Marine actinomycete taxon for drug and fermentation product discovery

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,144,723
App. No.
09/991,518
Granted
Dec 5, 2006
Kind
B2
Abstract

The invention is the discovery of an actinomycete genus, given the name Salinospora gen. nov., that displays an obligate requirement of seawater (Na + ) for growth and unique 16S rRNA signature nucleotides. The invention is also the use of the genus for the production and discovery of active biomolecules such as pharmaceutical agents, agrichemicals, immunomodifiers, enzymes and enzyme inhibitors.

Claims (11)

1. An isolated marine actinomycete having an obligate requirement of sodium for growth, wherein the marine actinomycete is a strain of Salinospora comprising 16S rRNAs SEQ ID NO:4 or 5.

2. The strain of Salinospora of claim 1 , wherein the strain of Salinospora is obtained from sediment.

3. The isolated strain of Salinospora of claim 1 , wherein SEQ ID NOs:4 or 5 have signature nucleotides not found in other Micromonosporaceae 16S rRNAs.

4. The isolated strain of Salinospora of claim 3 , wherein the signature nucleotides are numbered and identified in accordance to the E.coli 16S rRNA sequence, wherein a uridine or cytosine at position 207 is an adenosine; an adenosine or guanine at position 366 is a cytosine; an adenosine or guanine at position 467 is a uracil; an adenosine at position 468 is a uracil; and adenosine at position 1456 is a guanine.

5. The method for producing a biomolecule, comprising

culturing a strain of Salinospora of claim 1 in a sodium containing growth media, wherein the biomolecule is produced by the strain of Salinospora ;

collecting the strain of Salinospora or the sodium containing growth media containing the biomolecule; and extracting the biomolecule from the strain of Salinospora or the sodium containing growth media, thereby producing the biomolecule.

6. The method of claim 5 , wherein the growth media comprises sodium at a concentration of 450 mM.

7. An isolated strain of Salinospora having an obligate requirement of sodium for growth, wherein the strain of Salinospora is a strain of Salinospora comprising 16S rRNAs SEQ ID NO:4 or 5 and signature nucleotides therein, wherein the signature nucleotides are numbered and identified in accordance to the E.coli 16S rRNA sequence, wherein a uridine or cytosine at position 207 is an adenosine; an adenosine or guanine at position 366 is a cytosine; an adenosine or guanine at position 467 is a uracil; an adenosine at position 468 is a uracil; and adenosine at position 1456 is a guanine.

8. An isolated strain of Salinospora having an obligate requirement of sodium for growth, wherein the strain of Salinospora is a strain of Salinospora comprising a 16S rRNA and signature nucleotides therein, wherein the signature nucleotides are numbered and identified in accordance to the E.coli 16S rRNA sequence, wherein a uridine or cytosine at position 207 is an adenosine; an adenosine or guanine at position 366 is a cytosine; an adenosine or guanine at position 467 is a uracil; an adenosine at position 468 is a uracil; and adenosine at position 1456 is a guanine.

9. The strain of Salinospora of claims 4 , 7 or 8 , wherein the strain of Salinospora is obtained from sediment.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Nov 15, 2016
From: HBM VIOVENTURES (CAYMAN) LTD.; HBM BIOCAPITAL (EUR) L.P.; HBM BIOCAPITAL (USD) L.P.; PRIVATE LIFE BIOMED AG; ALSTERTOR PRIVATE LIFE GMBH & CO. KG; ADVENT HEALTHCARE AND LIFE SCIENCES III LIMITED PARTNERSHIP; ADVENT HEALTHCARE AND LIFE SCIENCES III-A LIMITED PARTNERSHIP; ADVENT PARTNERS HLS III LIMITED PARTNERSHIP; PACIFIC VENTURE GROUP II, L.P.; PVG ASSOCIATES II, L.P.; FORWARD VENTURES IV, L.P.; FORWARD VENTURES IV B, L.P.; GIMV N.V.; GIMV ADVIESBEHEER LIFE SCIENCES N.V.; LOTUS BIOSCIENCE INVESTMENT HOLDS LTD; NOVARTIS BIOVENTURE FUND / NOVARTIS INTERNATIONAL AIG; HENSLER, MARY; JACOBS, ROBERT; WS INVESTMENT COMPANY; GENAVENT PARTNERS LP; ASTELLAS VENTURE FUND I LP; ROCHE FINANCE LTD; ALTA CALIFORNIA PARTNERS II, L.P.; ALTA EMBARCARDERO PARTNER II, LLC; ALTA CALIFORNIA PARTNERS II, L.P. - NEW POOL
To: NEREUS PHARMACEUTICALS, INC.
Reel/Frame 040327/0264 →
SECURITY AGREEMENT Recorded Aug 11, 2004
From: NEREUS PHARMACEUTICALS, INC.
To: ALTA CALIFORNIA PARTNERS II, L.P.; ALTA EMBARCADERO PARTNERS II, LLC; FORWARD VENTURES IV, L.P.; FORWARD VENTURES IV B, L.P.; FORWARD VENTURES III, L.P.; FORWARD VENTURES III INSTITUTIONAL PARTNERS, L.P.; GIMV N.V.; GIMV ADVIESBEHEEER LIFE SCIENCES N.V.; PACIFIC VENTURE GROUP II, L.P.; PVG ASSOCIATES II, L.P.
Reel/Frame 015017/0484 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2002
From: FENICAL, WILLIAM; JENSEN, PAUL R.; MINCER, TRACY J.
To: REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 012626/0183 →
Continuity (2)
Provisional Application 6024935600 · Nov 16, 2000
Related Publication 20030157695A1 · Aug 21, 2003